Epitope-Based Vaccine Design against Novel Coronavirus SARS-CoV-2 Envelope Protein
Hanuman Singh Dagur1, Saurabh Singh Dhakar2, Apporva Gupta31Department of Biotechnology, Jaipur National University, Jaipur, India, 2Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, India, 3Department of Chemical Sciences, Indian Institute of Science Training and Research Bhopal, Madhya Pradesh, India,
Objectives: The outbreak of the 2019 novel coronavirus (SARS-CoV-2) has infected millions of people, with a large number of deaths across 200 countries. The sudden emergence of the virus leads to limited available therapies for SARS-CoV-2. Therefore, vaccines and antiviral medicines are in desperate need. Methods: This study took immune-informatics approaches to identify B- and T-cell epitopes for the envelope membrane protein (E) of SARS-CoV-2, followed by estimating their antigenicity and interactions with the human leukocyte antigen (HLA) alleles. Results: We identified three B cell epitopes (“NSSRVPD”, “SRVKNLNSSRV”, “SRVPDLLV”), two MHC class-I (“FLLVTLAIL”, “VSLVKPSFY”) and one MHC class-II binding T-cell epitopes (“LLFLAFVVFLLVTLA”), which showed highly antigenic features. Allergenicity, toxicity and physicochemical properties analysis confirmed the specificity and selectivity of epitopes. The stability and safety of epitopes were confirmed by digestion analysis. Conclusion: Epitopes were thus identified and some of them can be potential candidates for vaccine development. Keywords: Envelope Protein, SARS-CoV-2, Vaccine
Cite This Article
Singh Dagur H, Singh Dhakar S, Gupta A. Epitope-Based Vaccine Design against Novel Coronavirus SARS-CoV-2 Envelope Protein. EJMO. 2020; 4(3): 201-208
Corresponding Author: Hanuman Singh Dagur